We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Logos Biosystems

Logos Biosystems is the life science solutions of Aligned Genetics, Inc., dedicated to the development and commercial... read more Featured Products: More products

Download Mobile App




Automated Fluorescent Microbial Cell Counter Detects Urinary Tract Infection

By LabMedica International staff writers
Posted on 15 Jul 2020
Print article
Image: The QUANTOM Tx Microbial Cell Counter is an image-based, automated cell counter that can identify and count individual bacterial cells in minutes (Photo courtesy of Logos Biosystems).
Image: The QUANTOM Tx Microbial Cell Counter is an image-based, automated cell counter that can identify and count individual bacterial cells in minutes (Photo courtesy of Logos Biosystems).
Urinary tract infections (UTI) accounted for around 400,000 hospitalizations, resulting in an estimated cost burden of approximately USD 2.8 billion in the USA. Between 50% and 60% of adult women will have at least one UTI in their life, and close to 10% of postmenopausal women indicate that they had a UTI in the previous year.

A rapid urinalysis is usually conducted upon presentation with UTI‐related symptoms in patients. A rapid urinalysis screens the urine for ketones, proteins, reducing substances, red blood cells (RBC), white blood cells (WBC), nitrites, and pH levels outside the normal range (4.5 to 8.0). The most common pathogen associated with UTI globally is Escherichia coli.

Gastroenterologists and their associates at the Sinai Hospital (Baltimore, MD, USA) obtained clean‐catch urine samples from 10 healthy control subjects with a negative urinalysis result and 11 subjects with suspected UTI with a positive urinalysis and culture result for E. coli. Urine samples that received a positive result were plated onto blood agar and MacConkey medium for growth analysis. Urine samples were analyzed using the QUANTOM Tx Microbial Cell Counter (Logos Biosystems, Annandale, VA, USA) upon reception from the microbiology laboratory.

The scientists reported that the mean cellular concentration for the 11 E. coli‐positive samples was 1.01 × 108 cells/mL (range = 2.5 × 107–3.29 × 108 ± SD = 8.9 × 107). The average cellular concentration for the 10 control samples was 2.35 × 106 cells/mL (range = 9.42 × 105–5.93 × 106 ± SD = 1.56 × 106). The difference in cellular concentration between the E. coli‐positive and control groups was found to be statistically significant.

The authors concluded that the automated microbial cell counter represents a significant step toward high throughput, reproducible microbial cell observation, and quantification. A significant difference in cellular concentration was observed between E. coli‐positive UTI samples and controls measured with an automated microbial cell counter. Thus, automated microbial cell counters may serve important roles as preliminary screening tools in clinical diagnostic settings. The study was published on July 4, 2020 in the Journal of Clinical Laboratory Analysis.

Related Links:
Sinai Hospital
Logos Biosystems


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.